The Case CCC Radiation Resources Core Facility (RRCF) provides an essential service to the Cancer Center, since ionizing radiation has both carcinogenic and therapeutic roles in cancer and can produce viable, but non-reproductive cells for a variety of other studies. The Facility serves two types of cancer researchers: those studying the cancer-causing and cancer-treating actions of radiation, and those with primary interests in other topics for whom radiation is an essential tool, e.g., for killing cells to prepare feeder layers for growth of embryonic stem cells, or to study the immunogenic properties of cancer cells. The objectives of the RRCF are: 1) To maintain and operate ionizing radiation-producing devices for cancer researchers; 2) To consult with users concerning the instrumentation, the services, the training requirements, and if desired, the experimental design; 3) To train new users in proper operation of the equipment;and; 4) To provide support for implementation of new security regulations. The Radiation Resources Core supports researchers from 7 of the 8 Scientific Research Programs, with the heaviest use by the Hematopoietic Disorders Program. The RRCF supports research concerning the effects of radiation in which the interest is to determine the mechanism of its action or to improve radiation therapeutics. The facility also provides extensive services for those with other interests in cancer research, but for whom radiation is necessary for the construction of feeder layers, the ablation of the immune response of animals, or the sterilization of reagents, as exemplified by published studies of several other cancer researchers. For both categories of Cancer Center researchers, the RRCF is an essential resource without which their research could not be accomplished.
The Case Comprehensive Cancer Center is Northeast Ohio's only NCI designated comprehensive cancer center providing bench-to-bedside medical research involving partnerships between basic, clinical and population scientists to speed translation of laboratory discoveries into new prevention/intervention and cancer treatments.
|Zhao, S; Sedwick, D; Wang, Z (2015) Genetic alterations of protein tyrosine phosphatases in human cancers. Oncogene 34:3885-94|
|Dermawan, Josephine Kam Tai; Gurova, Katerina; Pink, John et al. (2014) Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-?B, and cell-cycle progression in non-small cell lung cancer. Mol Cancer Ther 13:2203-14|
|Brubaker, Douglas; Difeo, Analisa; Chen, Yanwen et al. (2014) Drug Intervention Response Predictions with PARADIGM (DIRPP) identifies drug resistant cancer cell lines and pathway mechanisms of resistance. Pac Symp Biocomput :125-35|
|Yori, Jennifer L; Lozada, Kristen L; Seachrist, Darcie D et al. (2014) Combined SFK/mTOR inhibition prevents rapamycin-induced feedback activation of AKT and elicits efficient tumor regression. Cancer Res 74:4762-71|
|Dabir, Snehal; Kluge, Amy; McColl, Karen et al. (2014) PIAS3 activates the intrinsic apoptotic pathway in non-small cell lung cancer cells independent of p53 status. Int J Cancer 134:1045-54|
|Zapanta Rinonos, Serendipity; Rai, Urvashi; Vereb, Sydney et al. (2014) Sequential logic of polarity determination during the haploid-to-diploid transition in Saccharomyces cerevisiae. Eukaryot Cell 13:1393-402|
|Sizemore, Gina M; Sizemore, Steven T; Seachrist, Darcie D et al. (2014) GABA(A) receptor pi (GABRP) stimulates basal-like breast cancer cell migration through activation of extracellular-regulated kinase 1/2 (ERK1/2). J Biol Chem 289:24102-13|
|Sossey-Alaoui, Khalid; Pluskota, Elzbieta; Davuluri, Gangarao et al. (2014) Kindlin-3 enhances breast cancer progression and metastasis by activating Twist-mediated angiogenesis. FASEB J 28:2260-71|
|Dotan, Efrat; Devarajan, Karthik; D'Silva, A James et al. (2014) Patterns of use and tolerance of anti-epidermal growth factor receptor antibodies in older adults with metastatic colorectal cancer. Clin Colorectal Cancer 13:192-8|
|Arachiche, Amal; de la Fuente, María; Nieman, Marvin T (2014) Platelet specific promoters are insufficient to express protease activated receptor 1 (PAR1) transgene in mouse platelets. PLoS One 9:e97724|
Showing the most recent 10 out of 975 publications